SlideShare a Scribd company logo
1 of 14
Download to read offline
CMTupdateSpring 2015
1-855-HELPCMT
www.hnf-cure.org
New Strategic Alliance with Rare Disease
Report (RDR)
By Allison Moore
Founder & CEO – HNF
We are excited to announce our new collaboration with Rare Disease Report (RDR)
to increase awareness of Charcot-Marie-Tooth (CMT) among the medical community.
RDR’s website, e-newsletter, and print publication offers an independent voice for the
Rare Disease Community. They strive to bring together medical, scientific, investment,
regulatory, and advocate professionals interested in rare diseases and orphan drugs.
Since HNF is focused on supporting and developing treatment options for CMT, this
collaboration can be groundbreaking towards advancing CMT disease awareness.
Through this new alliance, HNF will expand its outreach to support our new Health Care
Provider (HCP) education program, an initiative aimed at identifying expert HCP’s to
support the CMT Patient Community. This program provides clinicians with additional
tools to care for their patients such as best standard of practice guidelines, information
on genetic testing, and patient assistance programs. In addition, HNF preferred HCP’s
gain access to other preferred HNF CMT Providers to support the need for accurate
diagnosis, supportive treatments, and other educational materials.
With the help of RDR, we will reach an audience of over 60,000 clinicians through their
digital and print distribution channels. Throughout the year, RDR will produce video
interviews with CMT experts and industry leaders on the diagnosis and management
of patients with CMT, as well as provide insight about new research and clinical trials.
James Radke, PhD, Managing Editor of RDR said, “The rare disease community
functions best when all parties are part of the conversation. We look forward to
working with HNF and provide them with a means to expand their reach into the clinical
population.” Click here to view the HNF-RDR Partnership webpage.
As HNF’s Founder & CEO, I firmly believe that it is clear that HCP’s are unaware of
CMT, how to recognize the early symptoms, and how to manage this and related
inherited neuropathies. HNF plans to change that!
Finally, HNF is asking the community to please reach out via email at
info@hnf-cure.org and share the HCP’s you would like us to be made aware
of and why you would like to see them as part of the HCP directory. Please
provide name, address, and phone number.
Inside This Issue
Featured Article 1
TRIAD 2-5
GRIN 6
Community	 7-9
Team CMT 10-12
Upcoming Events 13
TM
The Hereditary Neuropathy
Foundation’s mission is to increase
awareness and accurate diagnosis
of Charcot-Marie-Tooth (CMT)
and related inherited neuropathies,
support patients and families with
critical information to improve
quality of life, and fund research
that will lead to treatments and cures.
2
A New Mouse Model for Charcot-Marie-Tooth (CMT2)
By Sean Ekins
Chief Science Officer – HNF
We were recently informed that The
Jackson Laboratory (JAX, a nonprofit
biomedical research institution
headquartered in Bar Harbor,
Maine) had taken delivery and will
be distributing a newly generated
CMT-related mouse model. The new
model expresses mutant mitofusin
2, a mitochondrial membrane protein
involved in mitochondrial fusion and
regulation of vascular smooth muscle
cell proliferation.
The creator of the mouse model,
Dr. David Pleasure of the University
of California at Davis designed the
mouse so that researchers have the
ability to specifically induce expression
of the mutant gene in a tissue of
interest. Dr. Pleasure said, “The
heterozygous mouse, which expresses
the mutant gene as a knockin in
the Rosa locus, shows a mild foot
deformity demonstrable by catwalk
analysis, as well as an imbalance in
muscle fiber types demonstrable by
immunohistology and histochemistry.
Initial histological analysis of tibial
nerve failed to document obvious axon
loss. The phenotype in these young
adult mice is subtle.” This project
was funded by HNF. We look forward
to Dr. Pleasure publishing his work in
due course. It may require additional
work to push the characterization of
the mouse further. We have made
the mouse model available without
license so that other researchers
can use and evaluate it freely. We
thank The Jackson Laboratory for
their considerable assistance and
willingness to distribute this mouse.
Additional information can be obtained
at The Jackson Laboratory strain
datasheet. Orders can be placed for
this mouse strain today, and the first
mouse should be ready to be shipped
by the end of the year.
The JAX mouse repository provides a
variety of other mouse models relevant
for CMT, and is actively seeking
additional models. Please contact
Mike Sasner at Mike.Sasner@jax.org.
HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD)
as a collaborative effort with academia, government and industry, to develop
treatments for CMT. Currently, TRIAD involves many groups that span the
drug discovery, drug development, and diagnostics continuum.
Axon
Is also known as a nerve fibre, a
long, slender projection of a nerve
cell, or neuron, that typically
conducts electrical impulses
away from the neuron’s cell body.
Heterozygous
Adiploidorganismisheterozygous
at a gene locus when its cells
contain two different alleles of a
gene.
Histochemistry
A branch of histology dealing
with the identification of chemical
components in cells and tissues.
Histology
A department of anatomy
dealing with the minute structure,
composition, and function of
tissues.
Immunohistology
The microscopic study of tissues
with the aid of antibodies that
bind to tissue components and
reveal their presence.
MFN2
Mitofusin 2 is a gene that encodes
amitochondrialmembraneprotein
that participates in mitochondrial
fusion and contributes to the
maintenance and operation of the
mitochondrial network.
Mitochondrial
Are a subunit within a cell
that plays an important role in
generating energy for the cell.
ROSA locus
Is a position used for constitutive,
ubiquitous gene expression in
mice.
Tibial Nerve
Is a branch of the sciatic nerve
and is found in the leg.
Glossary of Terms
Introducing Our Newest Scientific Advisory Board Member
3
HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD)
as a collaborative effort with academia, government and industry, to develop
treatments for CMT. Currently, TRIAD involves many groups that span the
drug discovery, drug development, and diagnostics continuum.
Dr. Scott Stromatt has a medical
degree from the University of Chicago
and an MBA from the University
of Colorado. He is board certified
in Internal Medicine and has over
26 years of biopharmaceutical
experience, including three years as a
biotechnology analyst for a Wall Street
investment firm.
Dr. Stromatt has conducted over 55
Phase 1 to Phase 4 clinical trials in
a wide variety of clinical indications,
including oncology, rheumatology,
pulmonology, gastroenterology, and
neurology. In the field of neurology, he
ran clinical trials with a novel growth
factor for Lou Gehrig’s disease, or
amyotrophic lateral sclerosis. He has
worked on various regulatory filings
including INDs, NDAs, BLAs, and
MAAs. Additionally, he has experience
in medical affairs with extensive market
and brand management support.
Currently, Dr. Stromatt is the Chief
Medical Officer at Emergent
BioSolutions in Seattle, WA – a
biotechnology company focused on
oncology, autoimmune disease, and
infectious diseases.
4
Greensboro Survey Study for Genetic Counseling and Genetic Testing
By Elizabeth Francisco
M.S. Genetic Counseling
The goal of this study was to explore the perceptions and
utilization of genetic counseling and testing by people with
Charcot-Marie-Tooth (CMT). It’s important to understand
what people with CMT think about genetic services and
what factors may be supporting or suppressing their access
to these services. Participants were recruited through the
Hereditary Neuropathy Foundation databases. The project
was Internal Review Board (IRB) approved at the University
of North Carolina at Greensboro.
HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD)
as a collaborative effort with academia, government and industry, to develop
treatments for CMT. Currently, TRIAD involves many groups that span the
drug discovery, drug development, and diagnostics continuum.
•	 53% of participants indicated that they had
been offered genetic testing, 7% indicated
that testing was not offered because a family
member had already undergone testing,
and the remainder were not offered testing.
•	 Of those offered, 79.6% chose to pursue testing.
•	 92.5% of those that received testing were
happy with their decision.	
•	 Of those who have not had testing, 71.6%
indicated they were interested in pursuing
genetic testing.	
•	 Those who had genetic testing were significantly
more likely to report access to research as a
benefit than those who have not had testing.
•	 Participants who had not had genetic testing
were more likely to express concern about
potential negatives from this service, including
increased worry about themselves and their
children post-test, increased chance of
discrimination, and most of all cost.	
•	 Only 5% of those who had genetic testing felt
that the cost of testing was a negative to their
experience. 62% of those who had never
received testing anticipated cost would be a
negative.
•	 724 participants completed the survey.
Not all participants responded to every
question, and incomplete surveys were
considered for the material that was provided.
•	 73% of participants indicated they had never been
offered an appointment with a genetic counselor.
•	 Of those that attended genetic counseling, 86%
were happy with their experience.
•	 Over half of participants who have not had
genetic counseling indicated they would be
interested in a referral to a genetic counselor.
•	 44.6% of participants who had not received
genetic counseling perceived cost could be a
negative of this service. Only 5.3% of those who
did have genetic counseling reported cost as a
negative.
Genetic Counseling Results
Genetic Testing Results
5
HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD)
as a collaborative effort with academia, government and industry, to develop
treatments for CMT. Currently, TRIAD involves many groups that span the
drug discovery, drug development, and diagnostics continuum.
•	 Genetic counseling is an important and helpful
service to patients with CMT.		
•	 Genetic counseling can help people with
CMT who are considering testing: 	
– Cost was an over-estimated negative by
people who had not had genetic counseling
or testing. Genetic counselors can research
appropriate testing strategies and help people
apply for insurance coverage to reduce cost.
– Participants who have not had genetic
testing were also more likely to be
worried about the potential for genetic
discrimination and increased anxiety after
testing. Talking with a genetic counseling
may help alleviate some of this concern.
•	 Meeting with a genetic counselor after testing
can help people with CMT understand their
results including inheritance, natural history
and progression, and research opportunities.	
•	 Barriers to genetic counseling:	
– Although genetic counseling is a great
resource for people with CMT, most are
not being referred to a genetic counselor.	
– It is important for genetic counselors to
reach out to the neurologists in their area to
alert them to the services they can offer.	
– Neurologists and other providers should
become educated on the benefits of
genetic counseling and be prepared to
provide people with CMT with accurate
information about benefits and potential
negatives of genetic counseling and testing,
and referrals to these services.	
– Education of the CMT community on what
options are available to them and their
potential benefits and negatives will allow
people with CMT to be their own advocates
and request referral to genetic counseling and
testing services.
Many participants who had genetic counseling
provided comments about their experience:
“She believed and really listened to my story and was
willingtotestme(withthegeneticist)fortheonlydisorder
I had ever come across that matched my symptoms
– CMT2C. When the results came back positive, she
explained the results in detail and promised to research
for more information since it is so rare. Although I am
still waiting on her report 3 months later, it was still a
very positive experience.”
When asked to elaborate on experience benefits
of genetic testing, many participants provided
comments:
“[My] Daughter [was] misdiagnosed for 7 years, [it
is] nice to [now] know [her diagnosis] and be able
to research and help others by being involved with
research on CMT1B.”
We also received many comments from participants
who are interested in testing, but have not yet had
testing:
“I would like to be certain of the type and inheritance of
my CMT to counsel my children.”
“My kids need to know if they are carriers of the
gene. They’re young adults and planning on having
children of their own, but they need to know if
they’ll get CMT (adult onset in our family).”	
“As part of the Hereditary Neuropathy Foundation’s
Health Care Provider (HCP) outreach program, HNF will
be working to educate the genetic counselor community
on the importance of identifying CMT, proper genetic
testing, and providing helpful information for patient
cost assistance programs.”
ConclusionComments
6
Support Hereditary Neuropathy Research
by joining the Global Registry for Inherited
Neuropathies (GRIN)
HNF Joins The Coalition for Clinical Trials Awareness (CCTA)
By Allison Moore
Founder & CEO – HNF
Whether you’ve taken a medication
today to manage a chronic disease or
simply to keep a headache at bay, you
know that medical innovations have
the power to change lives. But these
breakthroughs don’t just happen.
Developing new medicines is a
lengthy and complex process, relying
on heavily volunteer participation
to evaluate potential therapies for
safety and effectiveness. Volunteer
participation is also important in pre-
clinical work (natural history and
outcome measure endpoint studies)
leading up to clinical trials. Without the
patients who volunteer to participate in
clinical trials, the development of new
medicines would not be possible.
During Clinical Trials Awareness Week,
we recognize the individuals who have
made new, innovative treatments a
reality for patient’s worldwide – clinical
trial researchers and participants. By
shining a spotlight on these unsung
heroes, we can raise awareness about
the importance of participating in a
clinical trial.
Clinical trials may benefit participants
by providing them the opportunity
potentially to receive an investigational
drug that is not available to people
outside the trial. In addition, they
may receive treatment from a clinical
research team that provides careful
oversight of their medical condition.
For a new medication to receive
FDA approval, it must undergo
comprehensive testing on actual
patients. Yet finding participants
for these trials can often be slow,
exhausting and ultimately
unsuccessful. Research from the
Tufts Center for the Study of Drug
Development found that eleven
percent of trial sites fail to enroll even
a single patient. Thirty-seven percent
under-enroll, and those who do meet
their enrollment targets typically have
to double their original timeline.
CTAA is working to educate the public
on what is a clinical trial (see video).
We feel strongly that everyone should
have access to helpful information
about clinical trials and the opportunity
to determine if participating in a clinical
trial is the right choice for them. We
look forward to the day when industry
develops clinical trials for the CMT and
inherited neuropathy community.
We thank our Facebook fans and
Twitter followers for joining us in
supporting CTAA Awareness Week.
The Hereditary Neuropathy Foundation
is proud to be a member of The
Coaliation for Clinical Trials Awareness
and we look forward to playing a
leadership role with this organization
and this effort.
Awareness of Clinical Trials Week, May 4th – 8th, 2015
Clinical Trials Awareness Week was
May 4th – 8th and HNF recognizes the
unsungheroes–clinicaltrialresearchers
and participants who have made new,
innovative treatments a reality for
patients worldwide. ‪#‎CTAW2015
We hope by this time next year we will
be celebrating within our community
too. Let’s CURE CMT!
45 Shares, 293 Likes
Clinical trials advance scientific
knowledge that may lead to innovative
treatments. Help us in celebrating
Clinical Trials Awareness Week.‪
‪#‎CTAW2015
Join the Global Registry for Inherited
Neuropathies
20 Shares, 137 Likes
Social Media Buzz: Top Facebook Posts #CTAW2015
COMMUNITY
7
Our CMT Inspire Community, Soon to be 2,000 Strong!
By Joy Aldrich
CMT Advocacy Director – HNF
HNF has partnered with Inspire to
provide a safe online health and
wellness community in which patients,
families, friends, and caregivers
connect with one another for support
and information. Some of the HOT
topics currently being discussed
include “Pregnancy and CMT,”
“Types of AFOs/Leg Braces,” and,
“What You Wish Your Doctor Knew.”
If you have not joined us yet, please
take a minute to set up your profile
and join our community. Don’t forget
to add your picture to make things a
bit more personal. For more info on
the CMT Inspire Community, please
contact JoyAldrich@hnf-cure.org
10 Reasons to Join the CMT Inspire Community TODAY!
Control what you share with extensive privacy settings.
Get support for your health concerns.
Join multiple Inspire communities (i.e. Invisible Disease Alliance) to connect with more people.
Receive regular updates about the health topics you care about.
Connect with others who are dealing with the same health concerns.
Learn about treatments and therapies.
Get real life answers from others that are experiencing your disease firsthand.
Network with individuals that live in your area for face-to-face support.
Seek comfort at any hour that you are not alone in your struggles.
Discover opportunities to participate in clinical trials and other research.
Click here to join the CMT Inspire Community!
9
10
WHAT IT’S LIKE TO LIVE WITH CMT
Visit our website for your free copy of our latest Essential Guide,
What It Is Like to Live with CMT. Based on the findings of the
renowned Ph.D., Elizabeth Barrett and Dr. Carol Birdsall, the
booklet provides a moving and informative account of the daily
challenges and triumphs experienced by people with CMT.
88
COMMUNITY
By Laura F.
Growing up, I always knew I was
different than my friends. I couldn’t
run fast, tripped often (the scars on
my knees are a reminder), was lousy
at any sports-related activity, and was
generally weak and uncoordinated.
My friends accepted me as I was and
didn’t really question it, but sometimes
strangers would ask, “Why are you
limping?” or, “What’s wrong with your
leg?” I usually just brushed it off with
some lame excuse like I was tired, or I
“sprained” my ankle. I developed very
effective coping mechanisms to hide
my differences and, for the most part,
it worked well.
Looking back, I think it was more
noticeable than I cared to admit, but
most people were just too polite to
say anything, but when someone
was bold enough to ask, the question
created a ton of embarrassment for
me. I felt ashamed and humiliated. It
was a completely irrational way to feel
for something I was born with, but
because I grew up not knowing there
was a disease causing my problems
or see myself as “abnormal” I did not
even want to acknowledge it.
Charcot-Marie-Tooth (CMT) is an
insidious disease that creeps up and
progresses slowly. Gradually, you
forget what walking properly actually
feels like, or that you should have the
ability to move your toes or do squats.
So, for the first time in my life, I visited
a chiropodist (deals with assessment,
diagnosis, and treatment of the lower
limbs), who assessed me walking
barefoot. The look of shock and
surprise on his face was alarming. He
asked me to sit down and questioned
why no one in my family had noticed
the way I walked. How had I managed
to go this long without a diagnosis?
He used words like “neurological,”
“serious,” and “disease.” I was scared
and felt like I had just received a death
sentence. He confirmed that I had
CMT1A. Mystery solved. I was relieved
in a way. I didn’t care to know about all
the things that could happen to me in
the future. I just wanted to live my life.
I continued on through law school, got
married, was focused on work and
family. I was in my mid-twenties at
that point. Unfortunately, shortly after
getting married, the disease seemed
to escalate its downward progression.
We wanted to start a family right
away. I learned that CMT was one
of the diseases that could be tested
for using Preimplantation Genetic
Diagnosis (PGD). This involves in vitro
fertilization process with the extra step
of performing genetic testing on the
embryos prior to implantation in order
to transfer the embryos that are free
of CMT. I felt very fortunate that this
process was available because it gave
me a sense of control over ensuring
that my CMT did not persist into the
next generation. I was consumed with
fear over how my husband would be
affected if my CMT was passed on to
our child. Would he blame me? Would
he resent me? And how would I myself
deal with the guilt if my child was more
severely afflicted than I was? It was
for all these reasons that we opted
for PGD. As it turned out, the in vitro
process was unsuccessful for us and it
was heartbreaking because we knew
that all the embryos were healthy. So
we let it go and I became pregnant
naturally about a year later. We were
prepared for whatever outcome God
chose for us and were blessed with a
healthy baby girl, followed by another
precious daughter a few years later.
Many couples are successful with PGD
and this procedure may be a viable
option for those who are struggling
with the decision of whether to have
children.
Fast forward 15 years later, two
beautiful children, now 40 years old.
I am beginning a new chapter in my
life. I have let go of the shame. I have
let go of the embarrassment. I am
telling people that I have CMT. I was
fearful about what people would say,
what they would think, how I would
be regarded. Those self-limiting
beliefs that had kept me immobilized
and isolated were all in my head. No
one cared that I had CMT! Nothing
changed in how they treated me.
In fact, it has been liberating. It has
been a tremendous relief because I do
not have to pretend or put up a front
anymore! I can just be me. My friends
and family have embraced me without
making the CMT front and center. It’s
just a part of me, but not the essence
of me.
Now I am doing things that I never
would have done, even just a few
years ago. Recent changes in my
personal life have forced me to wake
up and break free of old programs, find
the real me, be who I really am, love
myself, gain back the confidence that
I once had. I look in the mirror and I
like what I see and who I am. I am truly
grateful for my life and the experiences
that have brought me to where I stand
today. I have met so many inspiring
and amazing people since reaching
out to the CMT community. My story
is not much different than many others
with CMT. It’s a journey for all of us.
It has ups and downs like anything in
life. But I feel CMT places us all on a
unique journey, one of compassion,
empathy, courage, resilience, and
determination. I am so blessed and
honored to be a part of the CMT family!
Accepting Myself for Who I Am
89
COMMUNITY
The Long Road to Diagnosis Renews
Dedication to Advocacy
By Stephanie Carmody
Growing up we called it “Steffi
disorder.” My friends and family were
as baffled as my expert neurologists. I
had been diagnosed with typical Spiral
Muscular Atrophy (SMA) as a toddler
but never followed its progression; I
never seemed to get weaker. My myriad
of symptoms was distinctly different
than anyone else’s I had ever met in
a lifetime living in the neuromuscular
community. I thought I might never
find my true diagnosis, let alone others
who share it with me.
Through the years, the need to find
an answer led me to my own online
research searching for any disorders
that seemed to fit my symptoms. I had
severe lower leg weakness and foot
deformitiesfrombirth,partialvocalcord
paresis, scoliosis, hand weakness, and
respiratory weakness with severe sleep
apnea that developed in adulthood.
Along with this weakness, however,
I maintained very strong upper body
and hip muscles which allowed me
to walk with KAFO’s and lofstrand
crutches into my mid-twenties. I had
never been able to bear weight on my
legs to stand, but when I received my
KAFO’s and walker at 18 months, I took
off walking and only grew stronger. Up
until last spring, no diagnosis seemed
to fit.
My life was forever changed when
I came across a blurb about newly
recognized atypical types of SMA
not related to the SMA gene. After
researching further, I discovered that
a gene named TRPV4 was found to
be related to three neuromuscular
disorders in 2009, 1) Charcot-Marie-
Tooth (CMT2C), 2) Scapuloperoneal
Spinal Muscular Atrophy, and 3)
Congenital Distal Spinal Muscular
Atrophy. When I found the list of
symptoms related to these disorders
I was floored; they matched mine
almost perfectly. I learned that these
three disorders were
now considered one
disorder, TRPV4
Hereditary Motor and
Sensory Neuropathy
(TRPV4 HN), with a
spectrum of severity.
Cautiously optimistic,
I asked to be tested.
Two weeks later I had
the answer I had been
seeking for 34 years. The results came
back positive. I was overwhelmed
with gratitude and excitement; I finally
knew what was going on in my body
and for the first time had a tangible
avenue for both finding others who
shared my diagnosis and advocating
for treatment.
At the time of my diagnosis, my genetic
counselor said there were only 25-30
documented cases in the world, with
only one other individual who shares
my exact mutation. Faced with such
a rare and newly identified disorder, I
realized that the challenges for us as
a community were going to be finding
each other, raising awareness of our
existence, and advocating for research
into treatments. I couldn’t help but find
it my mission.
To begin these efforts, I turned to social
media and posted in groups related
to CMT and hereditary neuropathy
searching for others who had tested
positive for TRPV4 HN. When I found a
few others, it was thrilling to finally be
in contact with people who understood
many of my experiences related to our
disorder. I was not alone. I started a
private Facebook group for us to share
experiences, research, and resources
specific to our disorder. Our group has
now grown to include eight of us who
share our diagnosis. I anticipate that
the group will grow as more and more
people previously misdiagnosed or
undiagnosed undergo genetic testing
and test positive. As far as I know, our
“gathering” of individuals with TRPV4
HN is the only one in the world.
Since TRPV4 HN is very debilitating
and can be life-threatening because of
respiratory involvement, the need for
research into treatments is critical. It is
a disorder of the calcium ion channels,
and research is hopeful for treatment
because the gene and its function
are so well known, and preliminary
research indicates that some of the
muscle weakness may be reversible.
The challenges now are identifying
patients by advocating for genetic
testing for previously undiagnosed or
misdiagnosed patients, and raising
awareness for the need for research to
investigate potential treatments.
What a difference a year makes;
from “Steffi disorder” to a definitive
diagnosis with hope for potential
treatments. When I look to the future,
I am hopeful for answers to the
remaining scientific questions. With
partners like the Hereditary Neuropathy
Foundation and Biopontis Alliance
for Rare Diseases, I envision a world
where, through treatments, individuals
diagnosed with TRPV4 HN won’t have
to live with its consequences.
Stephanie lives in North Carolina with
her husband and two cats. She has a
Master’s Degree from UNC-Chapel
Hill, and works in the healthcare field.
10
Q&A with Timmy Dixon,
a Bilateral Amputee with
Charcot-Marie-Tooth
(CMT1A)
By Courtney Hollett
Fundraising Coordinator – HNF
COURTNEY: Tell us about yourself.
TIMMY: I was born and raised in a
small town in the Blueridge Mountains
where everyone knows your first
name. It is very laidback and quiet, no
stoplights, no hustle and bustle, and
no rush whatsoever. I am a standout
in my town because I am unique and
have a story to tell.
COURTNEY: When were you
diagnosed with CMT? What type
do you have?
TIMMY: When I was growing up I
always had that feeling something
was different about me. I tried very
hard to fit in with my friends and that
was a huge challenge for me. I was
very clumsy growing up and found it
difficult to even walk a straight line. As
a kid you are usually pretty reluctant
to visit the doctor, but my parents
made me. At the young age of 14 I
found out I had CMT. A neurologist
administered an electromyography
(EMG) to check the speed of my nerve
conduction. As suspected, I had CMT.
My dad suspected I did because he
had CMT as well and struggled daily
to make the best out of life. I was very
young, scared, and in denial choosing
to ignore the disease and try to fit in
with everyone else.
COURTNEY: What were the events
that lead to bilateral amputee?
TIMMY: As I grew older things just
became more difficult to accomplish
and life was becoming overwhelming.
Daily tasks as simple as walking,
tying shoes and the ability to stand
for over 10 minutes became almost
impossible. I had to earn a living out
of high school so I tried my hand at
various places of employment. I would
last a few months, if lucky, and would
have to return home unable to take
the pain of standing on my feet. There
was always a hopeless feeling deep
inside me which is hard for me to deal
with growing up. Due to making some
bad decisions and having financial
burdens I was no longer able to keep
valuable doctor appointments and
checkups. In January 2012, I was
rushed to the emergency room and in
critical condition. I had been battling
foot ulcers and infection for the past
5 years and I was in danger for my
life. I was sent to Duke University
Medical Center where the preformed
emergency surgery to remove both
of my infection riddled feet. This
surgery was just the first of a series of
surgeries I would have to endure in the
upcoming months. The surgeon came
to talk to my family members when
the procedure was over. He told them
I was in serious need of action, if I had
been 1 day later I would have been a
dead man. After post-op infections,
contracting MRSA (a life-threatening
staph infection), and 4 surgeries later, I
am a bilateral below the knee amputee
(BBKA). The struggle of phantom pain
and wrestling with my prosthetics
every day is really trying to me, but I
have to keep pressing forward. I have
a cure to find and people to inspire, I
cannot just quit now!
COURTNEY: What are the
challenges you face with CMT?
TIMMY: While I was in transition to
my new life as an amputee I was
very unhealthy and overweight. The
physicians expressed their concern
to me before I came home from the
hospital. They told me it wasn’t going
to be easy for me carrying all the extra
weight around so I decided to make
a change, a chance at a better more
active life. I have always heard that
a good diet and exercise is the key
to weight loss, and here I sat with no
legs totally non-weight bearing while
I recovered. In 7 months, I managed
to lose 125 pounds by changing my
eating habits. I felt the healthiest I have
ever felt in my life. Losing the weight
was also a big benefit to my affects
11
from CMT helping me accomplish
goals that were merely a dream of
mine. I hear people tell me all the time
how they would love to lose weight but
they are in too much pain. Imagine not
having any legs and just endured major
surgeries and still accomplishing your
goals for a better life. My CMT is still
very visible and a daily struggle of mine
but, I have to keep pushing forward.
I am here for you and offer myself to
help you reach your true potential,
despite the physical altercations you
may be facing. Rome wasn’t built in a
day and neither are you, it takes a lot
of time and patience to overcome what
lies ahead.
COURTNEY: How has CMT changed
your life?
TIMMY: CMT has changed my life in
so many ways but I always look for
the positives and not the negatives. I
feel I have grown and became a more
caring person. I have humbled myself
because I do know the struggle of
living with CMT along with amputation.
Life is short; you go around this world
one time, make it count and live your
life to the fullest. Help your brothers
and sisters every chance you have
because you could very well be there
light of hope.
COURTNEY: How were your
feelings leading up to the TD Five
Boro Bike Tour?
TIMMY: I have to admit I was a little
nervous but excited to ride on behalf
of HNF to help find a cure for CMT.
Finding a cure for CMT has become a
passion of mine and I will grasp every
opportunity I am presented to help
make a difference. I see great things
happening for us in the future but now,
more than ever, we need to come
together and fight together. I have faith
in each and every one of you.
It’s not too late to sponsor me to reach
my fundraising goal!
Meet Team CMT Michael
Watkins From Braselton,
Georgia
By Courtney Hollett
Fundraising Coordinator – HNF
Michael lives in Braselton, GA and
is married with two great kids. He is
an avid cyclist and decided to go out
on a limb and throw his name in the
hat for a lottery trail race in Leadville,
Colorado. The Trail 100 MTB Race
which will take place August 15, 2015.
This trail race is widely considered one
of the toughest mountain biking races
in the country. The race is 103.3 miles
long, take place at elevations ranging
from 9,300′ above sea level at its
lowest point to 12,550′ at its highest
point and makes its riders climb a total
elevation gain of 12,612′ all in under 12
hours. 100 mile trail races are difficult,
but imagine having CMT? We are so
grateful that Michael reached out to
us to cheer him along the way as he
tackles this amazing feat!
Michael’s motivation is to show
everyone that having CMT does not
mean you can’t achieve things you and
others once thought were impossible.
“CMT may limit what my body can do,
but it will not and cannot limit my goals,
my will and my determination to bring
a finishers belt buckle back home”!
Michael trains 6 days a week and
has many hours to think. He stays
motivated during a tough day of
training by repeating this motto to
himself “sometimes we just have to
work a little harder than most to get
what we want and the harder you work
at something the greater the feeling
you have when it’s over”.
Follow Michael’s blog and consider
donating to his goal!
12
Run Like a Superhero to Benefit Autosomal Dominant Optic Atrophy (ADOA)
By Courtney Hollett
Fundraising Coordinator – HNF
On Saturday April 18, 2015, hundreds
of people hit the pavement dressed
like their favorite superhero to raise
awareness of a rare disease called
Autosomal Dominant Optic Atrophy
(ADOA). ADOA affects 1 in 50,000
people and mostly strikes in early
childhood.
Carolyn Nava organized the Superhero
5K in honor of her 4-year-old daughter
Jillian, who was born with this rare
disease. Currently, there is no cure –
and until one is found, Jillian will soon
lose her abilities to see and hear.
The race was followed by a family-fun
day in Lexington’s Virginia Hilton Park,
with local artists, a balloon maker,
vendors, food, and much more. A DJ
rocked the house to keep the runners
and walkers moving. The highlight of
the day was the guest of honor herself,
Jillian, as she showed off her dance
moves. At the end of the day the event
was a success raising over $9,000.
Plans are to make this an annual event.
In addition to this, Carolyn will plan on
coordinating multiple events in South
Carolina to continue raising awareness
as well as funds research. For
example, she and another two families
that have children affected with
ADOA have teamed up by organizing
a virtual Superhero 5K. Runners can
run anywhere, any day between April
20th – June 30th. Please help these
families reach their goal of $50,000 by
December 31, 2015.
Click here for information and to
register. Remember that every dollar,
no matter how small, can help prevent
these kids from losing their eyesight.
Team CMT Takes On the TD Five Boro Bike Tour
By Courtney Hollett
Fundraising Coordinator – HNF
On Sunday May 3rd, 2015, twelve
Team CMT members biked through
the five boroughs of New York City on
streets totally free of cars. The day was
picturesque with not a cloud in the sky.
One member that had never been to
New York City stated “I definitely felt
the love this weekend in New York
City.” These twelve individuals were
raising funds for HNF’s Therapeutic
Research In Accelerated Discovery
program (TRIAD). We are thankful
for our riders and donors for their
continued support as we raised
$20,000 for CMT research.
Click here, it’s not too late to donate
to the TD Five Boro Bike Tour!
“HNF is so grateful to the TD Five Boro
Bike Tour for their continued support
year after year.”
– Allison Moore
Founder & CEO – HNF
UPCOMING EVENTS
1751 Second Ave, Suite 103
New York NY 10128
@CMTNeuropathy
HereditaryNeuropathyFoundation
hnf-cure.org
432 Park Avenue South, 4th Fl.
New York, NY 10016
The Virtual Superhero 5k
April 20 – June 30, 2015
Anyplace you want
Grace’s Courage Crusade
Sunday, August 16, 2015
Narragansett, Rhode Island
The Rochester Chrome Divas
Saturday, July 25, 2015
Rochester, New York
Pizza With a Purpose
September 14 – 16, 2015
New York, New York
Dick Sharpe Memorial Golf Outing
Thursday, September 17, 2015
Plandome Country Club
Manhasset, New York
Spin NYC at Crank
Fall 2015
New York, New York
13
Save the Date
For more information or questions about upcoming events, please email Courtney@hnf-cure.org
Cmt newsletter-spring-2015

More Related Content

What's hot

Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...HopkinsCFAR
 
Elsevier Interview - Dr Jorgensen - May 2015
Elsevier Interview - Dr Jorgensen - May 2015Elsevier Interview - Dr Jorgensen - May 2015
Elsevier Interview - Dr Jorgensen - May 2015jantrost
 
Personalized Medicine's Effect on Oncologists' Treatment Regimens
Personalized Medicine's Effect on Oncologists' Treatment RegimensPersonalized Medicine's Effect on Oncologists' Treatment Regimens
Personalized Medicine's Effect on Oncologists' Treatment RegimensIndustry Standard Research
 
SVMPharma Real World Evidence - Randomised controlled trials were never desig...
SVMPharma Real World Evidence - Randomised controlled trials were never desig...SVMPharma Real World Evidence - Randomised controlled trials were never desig...
SVMPharma Real World Evidence - Randomised controlled trials were never desig...SVMPharma Limited
 
Brindley aegate ams 2.2
Brindley aegate ams 2.2Brindley aegate ams 2.2
Brindley aegate ams 2.2Aegate
 
Chapter 15 precision medicine in oncology
Chapter 15 precision medicine in oncologyChapter 15 precision medicine in oncology
Chapter 15 precision medicine in oncologyNilesh Kucha
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environmentspmaugeri
 
Tools and Technology for Advancing Rare Disease Research and Drug Development
Tools and Technology for Advancing Rare Disease Research and Drug DevelopmentTools and Technology for Advancing Rare Disease Research and Drug Development
Tools and Technology for Advancing Rare Disease Research and Drug DevelopmentCovance
 
The story of personalized medicine
The story of personalized medicineThe story of personalized medicine
The story of personalized medicineSeth Taylor
 
Cellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformCellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformLavance L. Northington
 
The involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy surveyThe involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy surveyCanadian Cancer Survivor Network
 
New healthreport 2012
New healthreport 2012New healthreport 2012
New healthreport 2012Quintiles
 
Acs finding promiscuous old drugs for new uses-final
Acs   finding promiscuous old drugs for new uses-finalAcs   finding promiscuous old drugs for new uses-final
Acs finding promiscuous old drugs for new uses-finalSean Ekins
 
Human Papillomavirus Immunization completion rates increased by the use of th...
Human Papillomavirus Immunization completion rates increased by the use of th...Human Papillomavirus Immunization completion rates increased by the use of th...
Human Papillomavirus Immunization completion rates increased by the use of th...inventionjournals
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalTrimed Media Group
 

What's hot (20)

DTC Testing
DTC TestingDTC Testing
DTC Testing
 
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
Using Urine Point-of-Care Tenofovir Testing to Deliver Targeted PrEP Adherenc...
 
Elsevier Interview - Dr Jorgensen - May 2015
Elsevier Interview - Dr Jorgensen - May 2015Elsevier Interview - Dr Jorgensen - May 2015
Elsevier Interview - Dr Jorgensen - May 2015
 
Personalized Medicine's Effect on Oncologists' Treatment Regimens
Personalized Medicine's Effect on Oncologists' Treatment RegimensPersonalized Medicine's Effect on Oncologists' Treatment Regimens
Personalized Medicine's Effect on Oncologists' Treatment Regimens
 
SVMPharma Real World Evidence - Randomised controlled trials were never desig...
SVMPharma Real World Evidence - Randomised controlled trials were never desig...SVMPharma Real World Evidence - Randomised controlled trials were never desig...
SVMPharma Real World Evidence - Randomised controlled trials were never desig...
 
Brindley aegate ams 2.2
Brindley aegate ams 2.2Brindley aegate ams 2.2
Brindley aegate ams 2.2
 
Chapter 15 precision medicine in oncology
Chapter 15 precision medicine in oncologyChapter 15 precision medicine in oncology
Chapter 15 precision medicine in oncology
 
Development of drugs in public-private partnership (PPP) environments
Development of drugs in  public-private partnership (PPP) environmentsDevelopment of drugs in  public-private partnership (PPP) environments
Development of drugs in public-private partnership (PPP) environments
 
Cardiology04 (1)
Cardiology04 (1)Cardiology04 (1)
Cardiology04 (1)
 
Tools and Technology for Advancing Rare Disease Research and Drug Development
Tools and Technology for Advancing Rare Disease Research and Drug DevelopmentTools and Technology for Advancing Rare Disease Research and Drug Development
Tools and Technology for Advancing Rare Disease Research and Drug Development
 
Precision Medicine in Oncology
Precision Medicine in OncologyPrecision Medicine in Oncology
Precision Medicine in Oncology
 
AACR 2015
AACR 2015AACR 2015
AACR 2015
 
The story of personalized medicine
The story of personalized medicineThe story of personalized medicine
The story of personalized medicine
 
Cellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformCellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic Platform
 
The involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy surveyThe involvement of patients and survivors in volunteer advocacy survey
The involvement of patients and survivors in volunteer advocacy survey
 
New healthreport 2012
New healthreport 2012New healthreport 2012
New healthreport 2012
 
Hta basic introduction
Hta basic introductionHta basic introduction
Hta basic introduction
 
Acs finding promiscuous old drugs for new uses-final
Acs   finding promiscuous old drugs for new uses-finalAcs   finding promiscuous old drugs for new uses-final
Acs finding promiscuous old drugs for new uses-final
 
Human Papillomavirus Immunization completion rates increased by the use of th...
Human Papillomavirus Immunization completion rates increased by the use of th...Human Papillomavirus Immunization completion rates increased by the use of th...
Human Papillomavirus Immunization completion rates increased by the use of th...
 
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf finalAos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final
 

Viewers also liked

Standardization Activities: ISO/IEC JTC1 SC36
Standardization Activities: ISO/IEC JTC1 SC36Standardization Activities: ISO/IEC JTC1 SC36
Standardization Activities: ISO/IEC JTC1 SC36openforum
 
Acs talk data intensive drug design v2
Acs talk data intensive drug design v2Acs talk data intensive drug design v2
Acs talk data intensive drug design v2Sean Ekins
 
New Target Prediction and Visualization Tools Incorporating Open Source Molec...
New Target Prediction and Visualization Tools Incorporating Open Source Molec...New Target Prediction and Visualization Tools Incorporating Open Source Molec...
New Target Prediction and Visualization Tools Incorporating Open Source Molec...Sean Ekins
 
#ZikaOpen: Homology Models -
#ZikaOpen: Homology Models - #ZikaOpen: Homology Models -
#ZikaOpen: Homology Models - Sean Ekins
 
Why there needs to be open data for ultra-rare and rare disease drug discovery
Why there needs to be open data for ultra-rare and rare disease drug discoveryWhy there needs to be open data for ultra-rare and rare disease drug discovery
Why there needs to be open data for ultra-rare and rare disease drug discoverySean Ekins
 
The Development of Skills Structured Standard for IT Industry
The Development of Skills Structured Standard for IT IndustryThe Development of Skills Structured Standard for IT Industry
The Development of Skills Structured Standard for IT Industryopenforum
 
BioIT Drug induced liver injury talk 2011
BioIT Drug induced liver injury talk 2011BioIT Drug induced liver injury talk 2011
BioIT Drug induced liver injury talk 2011Sean Ekins
 
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...Sean Ekins
 
CDD Models case study #1
CDD Models case study #1 CDD Models case study #1
CDD Models case study #1 Sean Ekins
 
CDD models case study #2
CDD models case study #2 CDD models case study #2
CDD models case study #2 Sean Ekins
 
Collaborative Technologies for Biomedical Research
Collaborative Technologies for Biomedical ResearchCollaborative Technologies for Biomedical Research
Collaborative Technologies for Biomedical ResearchSean Ekins
 
CDD models case study #3
CDD models case study #3 CDD models case study #3
CDD models case study #3 Sean Ekins
 
Slas talk 2016
Slas talk 2016Slas talk 2016
Slas talk 2016Sean Ekins
 
Applying cheminformatics and bioinformatics approaches to neglected tropical ...
Applying cheminformatics and bioinformatics approaches to neglected tropical ...Applying cheminformatics and bioinformatics approaches to neglected tropical ...
Applying cheminformatics and bioinformatics approaches to neglected tropical ...Sean Ekins
 
Mining 'Bigger' Datasets to Create, Validate and Share Machine Learning Models
Mining 'Bigger' Datasets to Create, Validate and Share Machine Learning ModelsMining 'Bigger' Datasets to Create, Validate and Share Machine Learning Models
Mining 'Bigger' Datasets to Create, Validate and Share Machine Learning ModelsSean Ekins
 
Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...
Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...
Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...Sean Ekins
 
Development and sharing of ADME/Tox and Drug Discovery Machine learning models
Development and sharing of ADME/Tox and Drug Discovery Machine learning modelsDevelopment and sharing of ADME/Tox and Drug Discovery Machine learning models
Development and sharing of ADME/Tox and Drug Discovery Machine learning modelsSean Ekins
 
Observatoire départemental de l'eau - Eure 2012
Observatoire départemental de l'eau - Eure 2012Observatoire départemental de l'eau - Eure 2012
Observatoire départemental de l'eau - Eure 2012cg27
 
Stratégie de contenu numérique - Édition Restauration 2015
Stratégie de contenu numérique - Édition Restauration 2015Stratégie de contenu numérique - Édition Restauration 2015
Stratégie de contenu numérique - Édition Restauration 2015Gigi Huynh
 

Viewers also liked (20)

Standardization Activities: ISO/IEC JTC1 SC36
Standardization Activities: ISO/IEC JTC1 SC36Standardization Activities: ISO/IEC JTC1 SC36
Standardization Activities: ISO/IEC JTC1 SC36
 
Acs talk data intensive drug design v2
Acs talk data intensive drug design v2Acs talk data intensive drug design v2
Acs talk data intensive drug design v2
 
New Target Prediction and Visualization Tools Incorporating Open Source Molec...
New Target Prediction and Visualization Tools Incorporating Open Source Molec...New Target Prediction and Visualization Tools Incorporating Open Source Molec...
New Target Prediction and Visualization Tools Incorporating Open Source Molec...
 
#ZikaOpen: Homology Models -
#ZikaOpen: Homology Models - #ZikaOpen: Homology Models -
#ZikaOpen: Homology Models -
 
Why there needs to be open data for ultra-rare and rare disease drug discovery
Why there needs to be open data for ultra-rare and rare disease drug discoveryWhy there needs to be open data for ultra-rare and rare disease drug discovery
Why there needs to be open data for ultra-rare and rare disease drug discovery
 
The Development of Skills Structured Standard for IT Industry
The Development of Skills Structured Standard for IT IndustryThe Development of Skills Structured Standard for IT Industry
The Development of Skills Structured Standard for IT Industry
 
BioIT Drug induced liver injury talk 2011
BioIT Drug induced liver injury talk 2011BioIT Drug induced liver injury talk 2011
BioIT Drug induced liver injury talk 2011
 
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...
CDD: Vault, CDD: Vision and CDD: Models software for biologists and chemists ...
 
CDD Models case study #1
CDD Models case study #1 CDD Models case study #1
CDD Models case study #1
 
CDD models case study #2
CDD models case study #2 CDD models case study #2
CDD models case study #2
 
Collaborative Technologies for Biomedical Research
Collaborative Technologies for Biomedical ResearchCollaborative Technologies for Biomedical Research
Collaborative Technologies for Biomedical Research
 
CDD models case study #3
CDD models case study #3 CDD models case study #3
CDD models case study #3
 
Slas talk 2016
Slas talk 2016Slas talk 2016
Slas talk 2016
 
Applying cheminformatics and bioinformatics approaches to neglected tropical ...
Applying cheminformatics and bioinformatics approaches to neglected tropical ...Applying cheminformatics and bioinformatics approaches to neglected tropical ...
Applying cheminformatics and bioinformatics approaches to neglected tropical ...
 
Mining 'Bigger' Datasets to Create, Validate and Share Machine Learning Models
Mining 'Bigger' Datasets to Create, Validate and Share Machine Learning ModelsMining 'Bigger' Datasets to Create, Validate and Share Machine Learning Models
Mining 'Bigger' Datasets to Create, Validate and Share Machine Learning Models
 
The Necessary
The NecessaryThe Necessary
The Necessary
 
Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...
Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...
Using Machine Learning Models Based on Phenotypic Data to Discover New Molecu...
 
Development and sharing of ADME/Tox and Drug Discovery Machine learning models
Development and sharing of ADME/Tox and Drug Discovery Machine learning modelsDevelopment and sharing of ADME/Tox and Drug Discovery Machine learning models
Development and sharing of ADME/Tox and Drug Discovery Machine learning models
 
Observatoire départemental de l'eau - Eure 2012
Observatoire départemental de l'eau - Eure 2012Observatoire départemental de l'eau - Eure 2012
Observatoire départemental de l'eau - Eure 2012
 
Stratégie de contenu numérique - Édition Restauration 2015
Stratégie de contenu numérique - Édition Restauration 2015Stratégie de contenu numérique - Édition Restauration 2015
Stratégie de contenu numérique - Édition Restauration 2015
 

Similar to Cmt newsletter-spring-2015

CMT update 2014 fall
CMT update 2014 fallCMT update 2014 fall
CMT update 2014 fallSean Ekins
 
Cmt newsletter-winter-2015
Cmt newsletter-winter-2015Cmt newsletter-winter-2015
Cmt newsletter-winter-2015Sean Ekins
 
Cmt update-summer-newsletter-2015
Cmt update-summer-newsletter-2015Cmt update-summer-newsletter-2015
Cmt update-summer-newsletter-2015Sean Ekins
 
Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...Pydesalud
 
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1Sumith Kularatne
 
Take a look at the below link and then answer the below questions .docx
Take a look at the below link and then answer the below questions .docxTake a look at the below link and then answer the below questions .docx
Take a look at the below link and then answer the below questions .docxssuserf9c51d
 
K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...
K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...
K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...Kostyantyn Bobyk
 
The one thing I'd fix
The one thing I'd fixThe one thing I'd fix
The one thing I'd fixSwati Piramal
 
Pgd discussion challengesconcerns
Pgd discussion challengesconcernsPgd discussion challengesconcerns
Pgd discussion challengesconcernst7260678
 
Internship Research Paper - UCDC F2014
Internship Research Paper - UCDC F2014Internship Research Paper - UCDC F2014
Internship Research Paper - UCDC F2014Nancy Matti
 
Direct To Consumer Genomics and the Future of Healthcare
Direct To Consumer Genomics and the Future of HealthcareDirect To Consumer Genomics and the Future of Healthcare
Direct To Consumer Genomics and the Future of HealthcareRyan Squire
 
Patient-centric social media for outcomes and pharmacovigilance consideration...
Patient-centric social media for outcomes and pharmacovigilance consideration...Patient-centric social media for outcomes and pharmacovigilance consideration...
Patient-centric social media for outcomes and pharmacovigilance consideration...Inspire
 
Use of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test DevelopmentUse of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test DevelopmentEMMAIntl
 
Clinical genomics spx
Clinical genomics   spxClinical genomics   spx
Clinical genomics spxDiane McKenna
 
Cmt update spring2014
Cmt update spring2014Cmt update spring2014
Cmt update spring2014Sean Ekins
 
Sophia Zilber - Mito research and data webinar - June 3, 2021
Sophia Zilber - Mito research and data webinar - June 3, 2021Sophia Zilber - Mito research and data webinar - June 3, 2021
Sophia Zilber - Mito research and data webinar - June 3, 2021SophiaZilber
 
Slides for rare disorders meeting
Slides for rare disorders meetingSlides for rare disorders meeting
Slides for rare disorders meetingSean Ekins
 
Project Management_DM Presentation
Project Management_DM PresentationProject Management_DM Presentation
Project Management_DM PresentationDaniela Margiotta
 
Advocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointAdvocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointIMSHealthRWES
 

Similar to Cmt newsletter-spring-2015 (20)

CMT update 2014 fall
CMT update 2014 fallCMT update 2014 fall
CMT update 2014 fall
 
Cmt newsletter-winter-2015
Cmt newsletter-winter-2015Cmt newsletter-winter-2015
Cmt newsletter-winter-2015
 
Cmt update-summer-newsletter-2015
Cmt update-summer-newsletter-2015Cmt update-summer-newsletter-2015
Cmt update-summer-newsletter-2015
 
Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...Participation of the population in decisions about their health and in the pr...
Participation of the population in decisions about their health and in the pr...
 
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
Sumith_Kularatne_Intl_Innovation_Cancer_Research_Media_LR-1
 
Take a look at the below link and then answer the below questions .docx
Take a look at the below link and then answer the below questions .docxTake a look at the below link and then answer the below questions .docx
Take a look at the below link and then answer the below questions .docx
 
K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...
K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...
K Bobyk - %22A Primer on Personalized Medicine - The Imminent Systemic Shift%...
 
The one thing I'd fix
The one thing I'd fixThe one thing I'd fix
The one thing I'd fix
 
Pgd discussion challengesconcerns
Pgd discussion challengesconcernsPgd discussion challengesconcerns
Pgd discussion challengesconcerns
 
Internship Research Paper - UCDC F2014
Internship Research Paper - UCDC F2014Internship Research Paper - UCDC F2014
Internship Research Paper - UCDC F2014
 
Direct To Consumer Genomics and the Future of Healthcare
Direct To Consumer Genomics and the Future of HealthcareDirect To Consumer Genomics and the Future of Healthcare
Direct To Consumer Genomics and the Future of Healthcare
 
Patient-centric social media for outcomes and pharmacovigilance consideration...
Patient-centric social media for outcomes and pharmacovigilance consideration...Patient-centric social media for outcomes and pharmacovigilance consideration...
Patient-centric social media for outcomes and pharmacovigilance consideration...
 
Use of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test DevelopmentUse of Genetic Databases to Advance Diagnostic Test Development
Use of Genetic Databases to Advance Diagnostic Test Development
 
SZI abstract
SZI abstractSZI abstract
SZI abstract
 
Clinical genomics spx
Clinical genomics   spxClinical genomics   spx
Clinical genomics spx
 
Cmt update spring2014
Cmt update spring2014Cmt update spring2014
Cmt update spring2014
 
Sophia Zilber - Mito research and data webinar - June 3, 2021
Sophia Zilber - Mito research and data webinar - June 3, 2021Sophia Zilber - Mito research and data webinar - June 3, 2021
Sophia Zilber - Mito research and data webinar - June 3, 2021
 
Slides for rare disorders meeting
Slides for rare disorders meetingSlides for rare disorders meeting
Slides for rare disorders meeting
 
Project Management_DM Presentation
Project Management_DM PresentationProject Management_DM Presentation
Project Management_DM Presentation
 
Advocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpointAdvocacy and the cancer patient viewpoint
Advocacy and the cancer patient viewpoint
 

More from Sean Ekins

How to Win a small business grant.pptx
How to Win a small business grant.pptxHow to Win a small business grant.pptx
How to Win a small business grant.pptxSean Ekins
 
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Sean Ekins
 
A presentation at the Global Genes rare drug development symposium on governm...
A presentation at the Global Genes rare drug development symposium on governm...A presentation at the Global Genes rare drug development symposium on governm...
A presentation at the Global Genes rare drug development symposium on governm...Sean Ekins
 
Leveraging Science Communication and Social Media to Build Your Brand and Ele...
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Leveraging Science Communication and Social Media to Build Your Brand and Ele...
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Sean Ekins
 
Bayesian Models for Chagas Disease
Bayesian Models for Chagas DiseaseBayesian Models for Chagas Disease
Bayesian Models for Chagas DiseaseSean Ekins
 
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Sean Ekins
 
Drug Discovery Today March 2017 special issue
Drug Discovery Today March 2017 special issueDrug Discovery Today March 2017 special issue
Drug Discovery Today March 2017 special issueSean Ekins
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesSean Ekins
 
Five Ways to Use Social Media to Raise Awareness for Your Paper or Research
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchFive Ways to Use Social Media to Raise Awareness for Your Paper or Research
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchSean Ekins
 
Open zika presentation
Open zika presentation Open zika presentation
Open zika presentation Sean Ekins
 
academic / small company collaborations for rare and neglected diseasesv2
 academic / small company collaborations for rare and neglected diseasesv2 academic / small company collaborations for rare and neglected diseasesv2
academic / small company collaborations for rare and neglected diseasesv2Sean Ekins
 
The future of computational chemistry b ig
The future of computational chemistry b igThe future of computational chemistry b ig
The future of computational chemistry b igSean Ekins
 
Pros and cons of social networking for scientists
Pros and cons of social networking for scientistsPros and cons of social networking for scientists
Pros and cons of social networking for scientistsSean Ekins
 
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery Collaborations
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery CollaborationsCDD: Vault, CDD: Vision and CDD: Models for Drug Discovery Collaborations
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery CollaborationsSean Ekins
 
Rare pediatric and neglected tropical diseases priority review voucher and tr...
Rare pediatric and neglected tropical diseases priority review voucher and tr...Rare pediatric and neglected tropical diseases priority review voucher and tr...
Rare pediatric and neglected tropical diseases priority review voucher and tr...Sean Ekins
 
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...Sean Ekins
 
C&E news talk sept 16
C&E news talk sept 16C&E news talk sept 16
C&E news talk sept 16Sean Ekins
 
Infographic for Sanfilippo Syndrome IIIC and IIID
Infographic for Sanfilippo Syndrome IIIC and IIIDInfographic for Sanfilippo Syndrome IIIC and IIID
Infographic for Sanfilippo Syndrome IIIC and IIIDSean Ekins
 
The value of the pediatric and tropical disease voucher - The golden ticket
The value of the pediatric and tropical disease voucher - The golden ticketThe value of the pediatric and tropical disease voucher - The golden ticket
The value of the pediatric and tropical disease voucher - The golden ticketSean Ekins
 
Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...
Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...
Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...Sean Ekins
 

More from Sean Ekins (20)

How to Win a small business grant.pptx
How to Win a small business grant.pptxHow to Win a small business grant.pptx
How to Win a small business grant.pptx
 
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...
Evaluating Multiple Machine Learning Models for Biodegradation and Aquatic To...
 
A presentation at the Global Genes rare drug development symposium on governm...
A presentation at the Global Genes rare drug development symposium on governm...A presentation at the Global Genes rare drug development symposium on governm...
A presentation at the Global Genes rare drug development symposium on governm...
 
Leveraging Science Communication and Social Media to Build Your Brand and Ele...
Leveraging Science Communication and Social Media to Build Your Brand and Ele...Leveraging Science Communication and Social Media to Build Your Brand and Ele...
Leveraging Science Communication and Social Media to Build Your Brand and Ele...
 
Bayesian Models for Chagas Disease
Bayesian Models for Chagas DiseaseBayesian Models for Chagas Disease
Bayesian Models for Chagas Disease
 
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...
Assay Central: A New Approach to Compiling Big Data and Preparing Machine Lea...
 
Drug Discovery Today March 2017 special issue
Drug Discovery Today March 2017 special issueDrug Discovery Today March 2017 special issue
Drug Discovery Today March 2017 special issue
 
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan DiseasesUsing In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
Using In Silico Tools in Repurposing Drugs for Neglected and Orphan Diseases
 
Five Ways to Use Social Media to Raise Awareness for Your Paper or Research
Five Ways to Use Social Media to Raise Awareness for Your Paper or ResearchFive Ways to Use Social Media to Raise Awareness for Your Paper or Research
Five Ways to Use Social Media to Raise Awareness for Your Paper or Research
 
Open zika presentation
Open zika presentation Open zika presentation
Open zika presentation
 
academic / small company collaborations for rare and neglected diseasesv2
 academic / small company collaborations for rare and neglected diseasesv2 academic / small company collaborations for rare and neglected diseasesv2
academic / small company collaborations for rare and neglected diseasesv2
 
The future of computational chemistry b ig
The future of computational chemistry b igThe future of computational chemistry b ig
The future of computational chemistry b ig
 
Pros and cons of social networking for scientists
Pros and cons of social networking for scientistsPros and cons of social networking for scientists
Pros and cons of social networking for scientists
 
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery Collaborations
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery CollaborationsCDD: Vault, CDD: Vision and CDD: Models for Drug Discovery Collaborations
CDD: Vault, CDD: Vision and CDD: Models for Drug Discovery Collaborations
 
Rare pediatric and neglected tropical diseases priority review voucher and tr...
Rare pediatric and neglected tropical diseases priority review voucher and tr...Rare pediatric and neglected tropical diseases priority review voucher and tr...
Rare pediatric and neglected tropical diseases priority review voucher and tr...
 
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...
Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Mode...
 
C&E news talk sept 16
C&E news talk sept 16C&E news talk sept 16
C&E news talk sept 16
 
Infographic for Sanfilippo Syndrome IIIC and IIID
Infographic for Sanfilippo Syndrome IIIC and IIIDInfographic for Sanfilippo Syndrome IIIC and IIID
Infographic for Sanfilippo Syndrome IIIC and IIID
 
The value of the pediatric and tropical disease voucher - The golden ticket
The value of the pediatric and tropical disease voucher - The golden ticketThe value of the pediatric and tropical disease voucher - The golden ticket
The value of the pediatric and tropical disease voucher - The golden ticket
 
Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...
Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...
Mobile Apps for transporter Drug-drug interaction prediction - a tool of the ...
 

Recently uploaded

Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...Call Girls in Nagpur High Profile
 
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...Arohi Goyal
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeCall Girls Delhi
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...chandars293
 
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...narwatsonia7
 
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...tanya dube
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escortsvidya singh
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Dipal Arora
 
Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...
Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...
Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...narwatsonia7
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...aartirawatdelhi
 
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...narwatsonia7
 
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...Taniya Sharma
 
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiRussian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiAlinaDevecerski
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomdiscovermytutordmt
 
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...Taniya Sharma
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...astropune
 
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableDipal Arora
 
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableDipal Arora
 

Recently uploaded (20)

Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
 
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
All Time Service Available Call Girls Marine Drive 📳 9820252231 For 18+ VIP C...
 
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Ludhiana Just Call 9907093804 Top Class Call Girl Service Available
 
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any TimeTop Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
Top Quality Call Girl Service Kalyanpur 6378878445 Available Call Girls Any Time
 
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...Top Rated  Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
Top Rated Hyderabad Call Girls Erragadda ⟟ 6297143586 ⟟ Call Me For Genuine ...
 
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
Top Rated Bangalore Call Girls Richmond Circle ⟟ 8250192130 ⟟ Call Me For Gen...
 
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
Premium Bangalore Call Girls Jigani Dail 6378878445 Escort Service For Hot Ma...
 
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore EscortsCall Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
Call Girls Horamavu WhatsApp Number 7001035870 Meeting With Bangalore Escorts
 
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
Call Girls Bhubaneswar Just Call 9907093804 Top Class Call Girl Service Avail...
 
Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...
Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...
Top Rated Bangalore Call Girls Ramamurthy Nagar ⟟ 8250192130 ⟟ Call Me For Ge...
 
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Coimbatore Just Call 9907093804 Top Class Call Girl Service Available
 
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
Night 7k to 12k Navi Mumbai Call Girl Photo 👉 BOOK NOW 9833363713 👈 ♀️ night ...
 
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
Top Rated Bangalore Call Girls Mg Road ⟟ 8250192130 ⟟ Call Me For Genuine Sex...
 
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
(👑VVIP ISHAAN ) Russian Call Girls Service Navi Mumbai🖕9920874524🖕Independent...
 
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls DelhiRussian Escorts Girls  Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
Russian Escorts Girls Nehru Place ZINATHI 🔝9711199012 ☪ 24/7 Call Girls Delhi
 
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel roomLucknow Call girls - 8800925952 - 24x7 service with hotel room
Lucknow Call girls - 8800925952 - 24x7 service with hotel room
 
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
💎VVIP Kolkata Call Girls Parganas🩱7001035870🩱Independent Girl ( Ac Rooms Avai...
 
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
♛VVIP Hyderabad Call Girls Chintalkunta🖕7001035870🖕Riya Kappor Top Call Girl ...
 
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service AvailableCall Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
Call Girls Gwalior Just Call 8617370543 Top Class Call Girl Service Available
 
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service AvailableCall Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
Call Girls Bareilly Just Call 9907093804 Top Class Call Girl Service Available
 

Cmt newsletter-spring-2015

  • 1. CMTupdateSpring 2015 1-855-HELPCMT www.hnf-cure.org New Strategic Alliance with Rare Disease Report (RDR) By Allison Moore Founder & CEO – HNF We are excited to announce our new collaboration with Rare Disease Report (RDR) to increase awareness of Charcot-Marie-Tooth (CMT) among the medical community. RDR’s website, e-newsletter, and print publication offers an independent voice for the Rare Disease Community. They strive to bring together medical, scientific, investment, regulatory, and advocate professionals interested in rare diseases and orphan drugs. Since HNF is focused on supporting and developing treatment options for CMT, this collaboration can be groundbreaking towards advancing CMT disease awareness. Through this new alliance, HNF will expand its outreach to support our new Health Care Provider (HCP) education program, an initiative aimed at identifying expert HCP’s to support the CMT Patient Community. This program provides clinicians with additional tools to care for their patients such as best standard of practice guidelines, information on genetic testing, and patient assistance programs. In addition, HNF preferred HCP’s gain access to other preferred HNF CMT Providers to support the need for accurate diagnosis, supportive treatments, and other educational materials. With the help of RDR, we will reach an audience of over 60,000 clinicians through their digital and print distribution channels. Throughout the year, RDR will produce video interviews with CMT experts and industry leaders on the diagnosis and management of patients with CMT, as well as provide insight about new research and clinical trials. James Radke, PhD, Managing Editor of RDR said, “The rare disease community functions best when all parties are part of the conversation. We look forward to working with HNF and provide them with a means to expand their reach into the clinical population.” Click here to view the HNF-RDR Partnership webpage. As HNF’s Founder & CEO, I firmly believe that it is clear that HCP’s are unaware of CMT, how to recognize the early symptoms, and how to manage this and related inherited neuropathies. HNF plans to change that! Finally, HNF is asking the community to please reach out via email at info@hnf-cure.org and share the HCP’s you would like us to be made aware of and why you would like to see them as part of the HCP directory. Please provide name, address, and phone number. Inside This Issue Featured Article 1 TRIAD 2-5 GRIN 6 Community 7-9 Team CMT 10-12 Upcoming Events 13 TM The Hereditary Neuropathy Foundation’s mission is to increase awareness and accurate diagnosis of Charcot-Marie-Tooth (CMT) and related inherited neuropathies, support patients and families with critical information to improve quality of life, and fund research that will lead to treatments and cures.
  • 2. 2 A New Mouse Model for Charcot-Marie-Tooth (CMT2) By Sean Ekins Chief Science Officer – HNF We were recently informed that The Jackson Laboratory (JAX, a nonprofit biomedical research institution headquartered in Bar Harbor, Maine) had taken delivery and will be distributing a newly generated CMT-related mouse model. The new model expresses mutant mitofusin 2, a mitochondrial membrane protein involved in mitochondrial fusion and regulation of vascular smooth muscle cell proliferation. The creator of the mouse model, Dr. David Pleasure of the University of California at Davis designed the mouse so that researchers have the ability to specifically induce expression of the mutant gene in a tissue of interest. Dr. Pleasure said, “The heterozygous mouse, which expresses the mutant gene as a knockin in the Rosa locus, shows a mild foot deformity demonstrable by catwalk analysis, as well as an imbalance in muscle fiber types demonstrable by immunohistology and histochemistry. Initial histological analysis of tibial nerve failed to document obvious axon loss. The phenotype in these young adult mice is subtle.” This project was funded by HNF. We look forward to Dr. Pleasure publishing his work in due course. It may require additional work to push the characterization of the mouse further. We have made the mouse model available without license so that other researchers can use and evaluate it freely. We thank The Jackson Laboratory for their considerable assistance and willingness to distribute this mouse. Additional information can be obtained at The Jackson Laboratory strain datasheet. Orders can be placed for this mouse strain today, and the first mouse should be ready to be shipped by the end of the year. The JAX mouse repository provides a variety of other mouse models relevant for CMT, and is actively seeking additional models. Please contact Mike Sasner at Mike.Sasner@jax.org. HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a collaborative effort with academia, government and industry, to develop treatments for CMT. Currently, TRIAD involves many groups that span the drug discovery, drug development, and diagnostics continuum. Axon Is also known as a nerve fibre, a long, slender projection of a nerve cell, or neuron, that typically conducts electrical impulses away from the neuron’s cell body. Heterozygous Adiploidorganismisheterozygous at a gene locus when its cells contain two different alleles of a gene. Histochemistry A branch of histology dealing with the identification of chemical components in cells and tissues. Histology A department of anatomy dealing with the minute structure, composition, and function of tissues. Immunohistology The microscopic study of tissues with the aid of antibodies that bind to tissue components and reveal their presence. MFN2 Mitofusin 2 is a gene that encodes amitochondrialmembraneprotein that participates in mitochondrial fusion and contributes to the maintenance and operation of the mitochondrial network. Mitochondrial Are a subunit within a cell that plays an important role in generating energy for the cell. ROSA locus Is a position used for constitutive, ubiquitous gene expression in mice. Tibial Nerve Is a branch of the sciatic nerve and is found in the leg. Glossary of Terms
  • 3. Introducing Our Newest Scientific Advisory Board Member 3 HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a collaborative effort with academia, government and industry, to develop treatments for CMT. Currently, TRIAD involves many groups that span the drug discovery, drug development, and diagnostics continuum. Dr. Scott Stromatt has a medical degree from the University of Chicago and an MBA from the University of Colorado. He is board certified in Internal Medicine and has over 26 years of biopharmaceutical experience, including three years as a biotechnology analyst for a Wall Street investment firm. Dr. Stromatt has conducted over 55 Phase 1 to Phase 4 clinical trials in a wide variety of clinical indications, including oncology, rheumatology, pulmonology, gastroenterology, and neurology. In the field of neurology, he ran clinical trials with a novel growth factor for Lou Gehrig’s disease, or amyotrophic lateral sclerosis. He has worked on various regulatory filings including INDs, NDAs, BLAs, and MAAs. Additionally, he has experience in medical affairs with extensive market and brand management support. Currently, Dr. Stromatt is the Chief Medical Officer at Emergent BioSolutions in Seattle, WA – a biotechnology company focused on oncology, autoimmune disease, and infectious diseases.
  • 4. 4 Greensboro Survey Study for Genetic Counseling and Genetic Testing By Elizabeth Francisco M.S. Genetic Counseling The goal of this study was to explore the perceptions and utilization of genetic counseling and testing by people with Charcot-Marie-Tooth (CMT). It’s important to understand what people with CMT think about genetic services and what factors may be supporting or suppressing their access to these services. Participants were recruited through the Hereditary Neuropathy Foundation databases. The project was Internal Review Board (IRB) approved at the University of North Carolina at Greensboro. HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a collaborative effort with academia, government and industry, to develop treatments for CMT. Currently, TRIAD involves many groups that span the drug discovery, drug development, and diagnostics continuum. • 53% of participants indicated that they had been offered genetic testing, 7% indicated that testing was not offered because a family member had already undergone testing, and the remainder were not offered testing. • Of those offered, 79.6% chose to pursue testing. • 92.5% of those that received testing were happy with their decision. • Of those who have not had testing, 71.6% indicated they were interested in pursuing genetic testing. • Those who had genetic testing were significantly more likely to report access to research as a benefit than those who have not had testing. • Participants who had not had genetic testing were more likely to express concern about potential negatives from this service, including increased worry about themselves and their children post-test, increased chance of discrimination, and most of all cost. • Only 5% of those who had genetic testing felt that the cost of testing was a negative to their experience. 62% of those who had never received testing anticipated cost would be a negative. • 724 participants completed the survey. Not all participants responded to every question, and incomplete surveys were considered for the material that was provided. • 73% of participants indicated they had never been offered an appointment with a genetic counselor. • Of those that attended genetic counseling, 86% were happy with their experience. • Over half of participants who have not had genetic counseling indicated they would be interested in a referral to a genetic counselor. • 44.6% of participants who had not received genetic counseling perceived cost could be a negative of this service. Only 5.3% of those who did have genetic counseling reported cost as a negative. Genetic Counseling Results Genetic Testing Results
  • 5. 5 HNF developed the Therapeutic Research in Accelerated Discovery (TRIAD) as a collaborative effort with academia, government and industry, to develop treatments for CMT. Currently, TRIAD involves many groups that span the drug discovery, drug development, and diagnostics continuum. • Genetic counseling is an important and helpful service to patients with CMT. • Genetic counseling can help people with CMT who are considering testing: – Cost was an over-estimated negative by people who had not had genetic counseling or testing. Genetic counselors can research appropriate testing strategies and help people apply for insurance coverage to reduce cost. – Participants who have not had genetic testing were also more likely to be worried about the potential for genetic discrimination and increased anxiety after testing. Talking with a genetic counseling may help alleviate some of this concern. • Meeting with a genetic counselor after testing can help people with CMT understand their results including inheritance, natural history and progression, and research opportunities. • Barriers to genetic counseling: – Although genetic counseling is a great resource for people with CMT, most are not being referred to a genetic counselor. – It is important for genetic counselors to reach out to the neurologists in their area to alert them to the services they can offer. – Neurologists and other providers should become educated on the benefits of genetic counseling and be prepared to provide people with CMT with accurate information about benefits and potential negatives of genetic counseling and testing, and referrals to these services. – Education of the CMT community on what options are available to them and their potential benefits and negatives will allow people with CMT to be their own advocates and request referral to genetic counseling and testing services. Many participants who had genetic counseling provided comments about their experience: “She believed and really listened to my story and was willingtotestme(withthegeneticist)fortheonlydisorder I had ever come across that matched my symptoms – CMT2C. When the results came back positive, she explained the results in detail and promised to research for more information since it is so rare. Although I am still waiting on her report 3 months later, it was still a very positive experience.” When asked to elaborate on experience benefits of genetic testing, many participants provided comments: “[My] Daughter [was] misdiagnosed for 7 years, [it is] nice to [now] know [her diagnosis] and be able to research and help others by being involved with research on CMT1B.” We also received many comments from participants who are interested in testing, but have not yet had testing: “I would like to be certain of the type and inheritance of my CMT to counsel my children.” “My kids need to know if they are carriers of the gene. They’re young adults and planning on having children of their own, but they need to know if they’ll get CMT (adult onset in our family).” “As part of the Hereditary Neuropathy Foundation’s Health Care Provider (HCP) outreach program, HNF will be working to educate the genetic counselor community on the importance of identifying CMT, proper genetic testing, and providing helpful information for patient cost assistance programs.” ConclusionComments
  • 6. 6 Support Hereditary Neuropathy Research by joining the Global Registry for Inherited Neuropathies (GRIN) HNF Joins The Coalition for Clinical Trials Awareness (CCTA) By Allison Moore Founder & CEO – HNF Whether you’ve taken a medication today to manage a chronic disease or simply to keep a headache at bay, you know that medical innovations have the power to change lives. But these breakthroughs don’t just happen. Developing new medicines is a lengthy and complex process, relying on heavily volunteer participation to evaluate potential therapies for safety and effectiveness. Volunteer participation is also important in pre- clinical work (natural history and outcome measure endpoint studies) leading up to clinical trials. Without the patients who volunteer to participate in clinical trials, the development of new medicines would not be possible. During Clinical Trials Awareness Week, we recognize the individuals who have made new, innovative treatments a reality for patient’s worldwide – clinical trial researchers and participants. By shining a spotlight on these unsung heroes, we can raise awareness about the importance of participating in a clinical trial. Clinical trials may benefit participants by providing them the opportunity potentially to receive an investigational drug that is not available to people outside the trial. In addition, they may receive treatment from a clinical research team that provides careful oversight of their medical condition. For a new medication to receive FDA approval, it must undergo comprehensive testing on actual patients. Yet finding participants for these trials can often be slow, exhausting and ultimately unsuccessful. Research from the Tufts Center for the Study of Drug Development found that eleven percent of trial sites fail to enroll even a single patient. Thirty-seven percent under-enroll, and those who do meet their enrollment targets typically have to double their original timeline. CTAA is working to educate the public on what is a clinical trial (see video). We feel strongly that everyone should have access to helpful information about clinical trials and the opportunity to determine if participating in a clinical trial is the right choice for them. We look forward to the day when industry develops clinical trials for the CMT and inherited neuropathy community. We thank our Facebook fans and Twitter followers for joining us in supporting CTAA Awareness Week. The Hereditary Neuropathy Foundation is proud to be a member of The Coaliation for Clinical Trials Awareness and we look forward to playing a leadership role with this organization and this effort. Awareness of Clinical Trials Week, May 4th – 8th, 2015 Clinical Trials Awareness Week was May 4th – 8th and HNF recognizes the unsungheroes–clinicaltrialresearchers and participants who have made new, innovative treatments a reality for patients worldwide. ‪#‎CTAW2015 We hope by this time next year we will be celebrating within our community too. Let’s CURE CMT! 45 Shares, 293 Likes Clinical trials advance scientific knowledge that may lead to innovative treatments. Help us in celebrating Clinical Trials Awareness Week.‪ ‪#‎CTAW2015 Join the Global Registry for Inherited Neuropathies 20 Shares, 137 Likes Social Media Buzz: Top Facebook Posts #CTAW2015
  • 7. COMMUNITY 7 Our CMT Inspire Community, Soon to be 2,000 Strong! By Joy Aldrich CMT Advocacy Director – HNF HNF has partnered with Inspire to provide a safe online health and wellness community in which patients, families, friends, and caregivers connect with one another for support and information. Some of the HOT topics currently being discussed include “Pregnancy and CMT,” “Types of AFOs/Leg Braces,” and, “What You Wish Your Doctor Knew.” If you have not joined us yet, please take a minute to set up your profile and join our community. Don’t forget to add your picture to make things a bit more personal. For more info on the CMT Inspire Community, please contact JoyAldrich@hnf-cure.org 10 Reasons to Join the CMT Inspire Community TODAY! Control what you share with extensive privacy settings. Get support for your health concerns. Join multiple Inspire communities (i.e. Invisible Disease Alliance) to connect with more people. Receive regular updates about the health topics you care about. Connect with others who are dealing with the same health concerns. Learn about treatments and therapies. Get real life answers from others that are experiencing your disease firsthand. Network with individuals that live in your area for face-to-face support. Seek comfort at any hour that you are not alone in your struggles. Discover opportunities to participate in clinical trials and other research. Click here to join the CMT Inspire Community! 9 10 WHAT IT’S LIKE TO LIVE WITH CMT Visit our website for your free copy of our latest Essential Guide, What It Is Like to Live with CMT. Based on the findings of the renowned Ph.D., Elizabeth Barrett and Dr. Carol Birdsall, the booklet provides a moving and informative account of the daily challenges and triumphs experienced by people with CMT.
  • 8. 88 COMMUNITY By Laura F. Growing up, I always knew I was different than my friends. I couldn’t run fast, tripped often (the scars on my knees are a reminder), was lousy at any sports-related activity, and was generally weak and uncoordinated. My friends accepted me as I was and didn’t really question it, but sometimes strangers would ask, “Why are you limping?” or, “What’s wrong with your leg?” I usually just brushed it off with some lame excuse like I was tired, or I “sprained” my ankle. I developed very effective coping mechanisms to hide my differences and, for the most part, it worked well. Looking back, I think it was more noticeable than I cared to admit, but most people were just too polite to say anything, but when someone was bold enough to ask, the question created a ton of embarrassment for me. I felt ashamed and humiliated. It was a completely irrational way to feel for something I was born with, but because I grew up not knowing there was a disease causing my problems or see myself as “abnormal” I did not even want to acknowledge it. Charcot-Marie-Tooth (CMT) is an insidious disease that creeps up and progresses slowly. Gradually, you forget what walking properly actually feels like, or that you should have the ability to move your toes or do squats. So, for the first time in my life, I visited a chiropodist (deals with assessment, diagnosis, and treatment of the lower limbs), who assessed me walking barefoot. The look of shock and surprise on his face was alarming. He asked me to sit down and questioned why no one in my family had noticed the way I walked. How had I managed to go this long without a diagnosis? He used words like “neurological,” “serious,” and “disease.” I was scared and felt like I had just received a death sentence. He confirmed that I had CMT1A. Mystery solved. I was relieved in a way. I didn’t care to know about all the things that could happen to me in the future. I just wanted to live my life. I continued on through law school, got married, was focused on work and family. I was in my mid-twenties at that point. Unfortunately, shortly after getting married, the disease seemed to escalate its downward progression. We wanted to start a family right away. I learned that CMT was one of the diseases that could be tested for using Preimplantation Genetic Diagnosis (PGD). This involves in vitro fertilization process with the extra step of performing genetic testing on the embryos prior to implantation in order to transfer the embryos that are free of CMT. I felt very fortunate that this process was available because it gave me a sense of control over ensuring that my CMT did not persist into the next generation. I was consumed with fear over how my husband would be affected if my CMT was passed on to our child. Would he blame me? Would he resent me? And how would I myself deal with the guilt if my child was more severely afflicted than I was? It was for all these reasons that we opted for PGD. As it turned out, the in vitro process was unsuccessful for us and it was heartbreaking because we knew that all the embryos were healthy. So we let it go and I became pregnant naturally about a year later. We were prepared for whatever outcome God chose for us and were blessed with a healthy baby girl, followed by another precious daughter a few years later. Many couples are successful with PGD and this procedure may be a viable option for those who are struggling with the decision of whether to have children. Fast forward 15 years later, two beautiful children, now 40 years old. I am beginning a new chapter in my life. I have let go of the shame. I have let go of the embarrassment. I am telling people that I have CMT. I was fearful about what people would say, what they would think, how I would be regarded. Those self-limiting beliefs that had kept me immobilized and isolated were all in my head. No one cared that I had CMT! Nothing changed in how they treated me. In fact, it has been liberating. It has been a tremendous relief because I do not have to pretend or put up a front anymore! I can just be me. My friends and family have embraced me without making the CMT front and center. It’s just a part of me, but not the essence of me. Now I am doing things that I never would have done, even just a few years ago. Recent changes in my personal life have forced me to wake up and break free of old programs, find the real me, be who I really am, love myself, gain back the confidence that I once had. I look in the mirror and I like what I see and who I am. I am truly grateful for my life and the experiences that have brought me to where I stand today. I have met so many inspiring and amazing people since reaching out to the CMT community. My story is not much different than many others with CMT. It’s a journey for all of us. It has ups and downs like anything in life. But I feel CMT places us all on a unique journey, one of compassion, empathy, courage, resilience, and determination. I am so blessed and honored to be a part of the CMT family! Accepting Myself for Who I Am
  • 9. 89 COMMUNITY The Long Road to Diagnosis Renews Dedication to Advocacy By Stephanie Carmody Growing up we called it “Steffi disorder.” My friends and family were as baffled as my expert neurologists. I had been diagnosed with typical Spiral Muscular Atrophy (SMA) as a toddler but never followed its progression; I never seemed to get weaker. My myriad of symptoms was distinctly different than anyone else’s I had ever met in a lifetime living in the neuromuscular community. I thought I might never find my true diagnosis, let alone others who share it with me. Through the years, the need to find an answer led me to my own online research searching for any disorders that seemed to fit my symptoms. I had severe lower leg weakness and foot deformitiesfrombirth,partialvocalcord paresis, scoliosis, hand weakness, and respiratory weakness with severe sleep apnea that developed in adulthood. Along with this weakness, however, I maintained very strong upper body and hip muscles which allowed me to walk with KAFO’s and lofstrand crutches into my mid-twenties. I had never been able to bear weight on my legs to stand, but when I received my KAFO’s and walker at 18 months, I took off walking and only grew stronger. Up until last spring, no diagnosis seemed to fit. My life was forever changed when I came across a blurb about newly recognized atypical types of SMA not related to the SMA gene. After researching further, I discovered that a gene named TRPV4 was found to be related to three neuromuscular disorders in 2009, 1) Charcot-Marie- Tooth (CMT2C), 2) Scapuloperoneal Spinal Muscular Atrophy, and 3) Congenital Distal Spinal Muscular Atrophy. When I found the list of symptoms related to these disorders I was floored; they matched mine almost perfectly. I learned that these three disorders were now considered one disorder, TRPV4 Hereditary Motor and Sensory Neuropathy (TRPV4 HN), with a spectrum of severity. Cautiously optimistic, I asked to be tested. Two weeks later I had the answer I had been seeking for 34 years. The results came back positive. I was overwhelmed with gratitude and excitement; I finally knew what was going on in my body and for the first time had a tangible avenue for both finding others who shared my diagnosis and advocating for treatment. At the time of my diagnosis, my genetic counselor said there were only 25-30 documented cases in the world, with only one other individual who shares my exact mutation. Faced with such a rare and newly identified disorder, I realized that the challenges for us as a community were going to be finding each other, raising awareness of our existence, and advocating for research into treatments. I couldn’t help but find it my mission. To begin these efforts, I turned to social media and posted in groups related to CMT and hereditary neuropathy searching for others who had tested positive for TRPV4 HN. When I found a few others, it was thrilling to finally be in contact with people who understood many of my experiences related to our disorder. I was not alone. I started a private Facebook group for us to share experiences, research, and resources specific to our disorder. Our group has now grown to include eight of us who share our diagnosis. I anticipate that the group will grow as more and more people previously misdiagnosed or undiagnosed undergo genetic testing and test positive. As far as I know, our “gathering” of individuals with TRPV4 HN is the only one in the world. Since TRPV4 HN is very debilitating and can be life-threatening because of respiratory involvement, the need for research into treatments is critical. It is a disorder of the calcium ion channels, and research is hopeful for treatment because the gene and its function are so well known, and preliminary research indicates that some of the muscle weakness may be reversible. The challenges now are identifying patients by advocating for genetic testing for previously undiagnosed or misdiagnosed patients, and raising awareness for the need for research to investigate potential treatments. What a difference a year makes; from “Steffi disorder” to a definitive diagnosis with hope for potential treatments. When I look to the future, I am hopeful for answers to the remaining scientific questions. With partners like the Hereditary Neuropathy Foundation and Biopontis Alliance for Rare Diseases, I envision a world where, through treatments, individuals diagnosed with TRPV4 HN won’t have to live with its consequences. Stephanie lives in North Carolina with her husband and two cats. She has a Master’s Degree from UNC-Chapel Hill, and works in the healthcare field.
  • 10. 10 Q&A with Timmy Dixon, a Bilateral Amputee with Charcot-Marie-Tooth (CMT1A) By Courtney Hollett Fundraising Coordinator – HNF COURTNEY: Tell us about yourself. TIMMY: I was born and raised in a small town in the Blueridge Mountains where everyone knows your first name. It is very laidback and quiet, no stoplights, no hustle and bustle, and no rush whatsoever. I am a standout in my town because I am unique and have a story to tell. COURTNEY: When were you diagnosed with CMT? What type do you have? TIMMY: When I was growing up I always had that feeling something was different about me. I tried very hard to fit in with my friends and that was a huge challenge for me. I was very clumsy growing up and found it difficult to even walk a straight line. As a kid you are usually pretty reluctant to visit the doctor, but my parents made me. At the young age of 14 I found out I had CMT. A neurologist administered an electromyography (EMG) to check the speed of my nerve conduction. As suspected, I had CMT. My dad suspected I did because he had CMT as well and struggled daily to make the best out of life. I was very young, scared, and in denial choosing to ignore the disease and try to fit in with everyone else. COURTNEY: What were the events that lead to bilateral amputee? TIMMY: As I grew older things just became more difficult to accomplish and life was becoming overwhelming. Daily tasks as simple as walking, tying shoes and the ability to stand for over 10 minutes became almost impossible. I had to earn a living out of high school so I tried my hand at various places of employment. I would last a few months, if lucky, and would have to return home unable to take the pain of standing on my feet. There was always a hopeless feeling deep inside me which is hard for me to deal with growing up. Due to making some bad decisions and having financial burdens I was no longer able to keep valuable doctor appointments and checkups. In January 2012, I was rushed to the emergency room and in critical condition. I had been battling foot ulcers and infection for the past 5 years and I was in danger for my life. I was sent to Duke University Medical Center where the preformed emergency surgery to remove both of my infection riddled feet. This surgery was just the first of a series of surgeries I would have to endure in the upcoming months. The surgeon came to talk to my family members when the procedure was over. He told them I was in serious need of action, if I had been 1 day later I would have been a dead man. After post-op infections, contracting MRSA (a life-threatening staph infection), and 4 surgeries later, I am a bilateral below the knee amputee (BBKA). The struggle of phantom pain and wrestling with my prosthetics every day is really trying to me, but I have to keep pressing forward. I have a cure to find and people to inspire, I cannot just quit now! COURTNEY: What are the challenges you face with CMT? TIMMY: While I was in transition to my new life as an amputee I was very unhealthy and overweight. The physicians expressed their concern to me before I came home from the hospital. They told me it wasn’t going to be easy for me carrying all the extra weight around so I decided to make a change, a chance at a better more active life. I have always heard that a good diet and exercise is the key to weight loss, and here I sat with no legs totally non-weight bearing while I recovered. In 7 months, I managed to lose 125 pounds by changing my eating habits. I felt the healthiest I have ever felt in my life. Losing the weight was also a big benefit to my affects
  • 11. 11 from CMT helping me accomplish goals that were merely a dream of mine. I hear people tell me all the time how they would love to lose weight but they are in too much pain. Imagine not having any legs and just endured major surgeries and still accomplishing your goals for a better life. My CMT is still very visible and a daily struggle of mine but, I have to keep pushing forward. I am here for you and offer myself to help you reach your true potential, despite the physical altercations you may be facing. Rome wasn’t built in a day and neither are you, it takes a lot of time and patience to overcome what lies ahead. COURTNEY: How has CMT changed your life? TIMMY: CMT has changed my life in so many ways but I always look for the positives and not the negatives. I feel I have grown and became a more caring person. I have humbled myself because I do know the struggle of living with CMT along with amputation. Life is short; you go around this world one time, make it count and live your life to the fullest. Help your brothers and sisters every chance you have because you could very well be there light of hope. COURTNEY: How were your feelings leading up to the TD Five Boro Bike Tour? TIMMY: I have to admit I was a little nervous but excited to ride on behalf of HNF to help find a cure for CMT. Finding a cure for CMT has become a passion of mine and I will grasp every opportunity I am presented to help make a difference. I see great things happening for us in the future but now, more than ever, we need to come together and fight together. I have faith in each and every one of you. It’s not too late to sponsor me to reach my fundraising goal! Meet Team CMT Michael Watkins From Braselton, Georgia By Courtney Hollett Fundraising Coordinator – HNF Michael lives in Braselton, GA and is married with two great kids. He is an avid cyclist and decided to go out on a limb and throw his name in the hat for a lottery trail race in Leadville, Colorado. The Trail 100 MTB Race which will take place August 15, 2015. This trail race is widely considered one of the toughest mountain biking races in the country. The race is 103.3 miles long, take place at elevations ranging from 9,300′ above sea level at its lowest point to 12,550′ at its highest point and makes its riders climb a total elevation gain of 12,612′ all in under 12 hours. 100 mile trail races are difficult, but imagine having CMT? We are so grateful that Michael reached out to us to cheer him along the way as he tackles this amazing feat! Michael’s motivation is to show everyone that having CMT does not mean you can’t achieve things you and others once thought were impossible. “CMT may limit what my body can do, but it will not and cannot limit my goals, my will and my determination to bring a finishers belt buckle back home”! Michael trains 6 days a week and has many hours to think. He stays motivated during a tough day of training by repeating this motto to himself “sometimes we just have to work a little harder than most to get what we want and the harder you work at something the greater the feeling you have when it’s over”. Follow Michael’s blog and consider donating to his goal!
  • 12. 12 Run Like a Superhero to Benefit Autosomal Dominant Optic Atrophy (ADOA) By Courtney Hollett Fundraising Coordinator – HNF On Saturday April 18, 2015, hundreds of people hit the pavement dressed like their favorite superhero to raise awareness of a rare disease called Autosomal Dominant Optic Atrophy (ADOA). ADOA affects 1 in 50,000 people and mostly strikes in early childhood. Carolyn Nava organized the Superhero 5K in honor of her 4-year-old daughter Jillian, who was born with this rare disease. Currently, there is no cure – and until one is found, Jillian will soon lose her abilities to see and hear. The race was followed by a family-fun day in Lexington’s Virginia Hilton Park, with local artists, a balloon maker, vendors, food, and much more. A DJ rocked the house to keep the runners and walkers moving. The highlight of the day was the guest of honor herself, Jillian, as she showed off her dance moves. At the end of the day the event was a success raising over $9,000. Plans are to make this an annual event. In addition to this, Carolyn will plan on coordinating multiple events in South Carolina to continue raising awareness as well as funds research. For example, she and another two families that have children affected with ADOA have teamed up by organizing a virtual Superhero 5K. Runners can run anywhere, any day between April 20th – June 30th. Please help these families reach their goal of $50,000 by December 31, 2015. Click here for information and to register. Remember that every dollar, no matter how small, can help prevent these kids from losing their eyesight. Team CMT Takes On the TD Five Boro Bike Tour By Courtney Hollett Fundraising Coordinator – HNF On Sunday May 3rd, 2015, twelve Team CMT members biked through the five boroughs of New York City on streets totally free of cars. The day was picturesque with not a cloud in the sky. One member that had never been to New York City stated “I definitely felt the love this weekend in New York City.” These twelve individuals were raising funds for HNF’s Therapeutic Research In Accelerated Discovery program (TRIAD). We are thankful for our riders and donors for their continued support as we raised $20,000 for CMT research. Click here, it’s not too late to donate to the TD Five Boro Bike Tour! “HNF is so grateful to the TD Five Boro Bike Tour for their continued support year after year.” – Allison Moore Founder & CEO – HNF
  • 13. UPCOMING EVENTS 1751 Second Ave, Suite 103 New York NY 10128 @CMTNeuropathy HereditaryNeuropathyFoundation hnf-cure.org 432 Park Avenue South, 4th Fl. New York, NY 10016 The Virtual Superhero 5k April 20 – June 30, 2015 Anyplace you want Grace’s Courage Crusade Sunday, August 16, 2015 Narragansett, Rhode Island The Rochester Chrome Divas Saturday, July 25, 2015 Rochester, New York Pizza With a Purpose September 14 – 16, 2015 New York, New York Dick Sharpe Memorial Golf Outing Thursday, September 17, 2015 Plandome Country Club Manhasset, New York Spin NYC at Crank Fall 2015 New York, New York 13 Save the Date For more information or questions about upcoming events, please email Courtney@hnf-cure.org